The new basal insulin analog glargine U-300 enables flexible injection schedule

Uru Nezu Osada, Yasuo Terauchi


Recently, Home et al. published a pre-planned continuation trial of EDITION 4 (1). EDITION 4 was a 6-month long, multicenter, randomized, and open-label clinical trial involving patients with type 1 diabetes mellitus (T1DM) who received a morning or evening injection of either 300 U/mL of insulin glargine (Gla-300) or 100 U/mL of insulin glargine (Gla-100) (1) to evaluate the safety, tolerability, and efficacy of both the dosages of the basal insulin analog.